Evolva Biotech Private Limited : Evolva Biotech was awarded the “Best synthetic biology company of the year 2011” for the European sector by Frost & Sullivan. This was presented in a glittering awards banquet as part of a two day global congress to foster growth and
innovation bringing together leaders from several industries and investors under one roof during May 17th and 18th 2011.
This award attains significance considering the fact that Evolva is one of the youngest companies amongst award recipients from several other fields as their technology is now having positive impact for Evolva’s collaborators, partners and investors globally. It is also one of the youngest companies to get listed much ahead of competition. Mr. Shriram Raghavan, who is co-ordinating operations for Evolva, represented the company at the event and received the award. “Evolva’s technology is useful on other verticals besides pharmaceuticals. This is the beginning of things to come from this technology feels Dr. P. M. Murali. “ This award is an endorsement of all in the company who worked towards the multiple application of the technology in diverse fields” said Mr. Neil Goldsmith. About the Best Practices award:
Frost & Sullivan is entering its 50th year in business with a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies. The Company’s research philosophy originates with the “CEO’s 360 Degree Perspective”, which in turn serves as the foundation of its “TEAM Research methodology”. This unique approach enables them to determine how best-in-class companies worldwide manage growth, innovation and leadership.
Based on the findings of this Best Practices research, Frost & Sullivan is proud to present the 2011
Also Read
Europe Company of the Year Award in Synthetic Biology to Evolva Holding SA. Their benchmarking criteria included growth strategy excellence, growth implementation excellence, degree of innovation with products and technologies, leadership in customer Value and market penetration potential.
